DarshanTalks Podcast

Send us Fan Mail

In this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni explores the unsettling transition from "Googling your symptoms" to "Chatting with your symptoms." It’s 10:47 PM—you have chest tightness and a chatbot is your only companion. But is the algorithm reassuring you, or is it gaslighting a medical emergency?

We go beyond the hype to examine the February 9, 2026, Nature Medicine study (as reported in the New York Times) which reveals a staggering gap between AI’s medical exam scores and its real-world ability to triage human beings. Darshan breaks down the "Black Box" of emergency room triage, the evolution of FDA Software as a Medical Device (SaMD) regulations, and why your zip code might determine if your data is protected under new 2026 state privacy laws in Washington, California, and Maryland.

Key topics include:

• The "Midnight Triage" Trap: Why AI struggles with the nuance of human shame, fear, and "atypical presentations" in the ER.
• FDA & the "Glass Box": Navigating the new 2026 guidance on Clinical Decision Support (CDS) software and the legal line between "wellness devices" and "medical devices."
• Liability & Malpractice: Why an algorithm can’t carry insurance—and what that means for the doctors who follow (or ignore) AI alerts.
• The Data Privacy Patchwork: How HIPAA fails you once you leave the hospital portal and enter the world of consumer AI chatbots.

Healthcare is a human endeavor, and accountability requires a human name. Learn how to use AI as a starting point without letting it be your final conclusion.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Special Advisory Bulletin, the government officially opened a "green lane" for direct-to-patient (DTP) drug sales, specifically addressing the rise of cash-pay programs like TrumpRx. In this episode, we break down why the OIG is now prioritizing lower costs over traditional Anti-Kickback Statute (AKS) risks for cash-paying patients—including those on Medicare and Medicaid. If you are a life sciences executive or legal counsel, this is the compliance roadmap you’ve been waiting for. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The DOJ just changed the rules of the game for the Life Sciences industry. As of January 2025, transferring "Bulk Sensitive Personal Data" to countries of concern—specifically China—is no longer just a compliance hurdle; it’s a potential federal violation. In this episode, Darshan Kulkarni breaks down the six categories of data you must protect immediately, from genomic data to precise geolocation. If you are handling safety data across borders, this is your mandatory executive briefing. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Is your state "sandbox" a playground or a legal minefield? In this episode, Darshan Kulkarni—pharmacist and attorney—dissects the quiet movement of states like Utah allowing AI to manage and renew prescriptions. While the innovation is exciting, the federal government is watching closely.

We break down the three massive risks facing life science companies and healthcare providers today:

1. Clinical Logic Failures: Why a state sandbox can't fix bad AI medicine.
2. The Liability Void: If the AI misses a symptom, who stands in court?
3. The Supremacy Clause: Why state "waivers" don't protect you from the FDA.

If you are navigating the intersection of health-tech and regulation, this is the practical take you need to stay compliant and protected.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 The OIG has officially shifted the goalposts for Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) programs. For years, federal healthcare discounts were a "no-go zone," but a new dual-track strategy is emerging—if you know how to build the firewall. In this episode, Darshan Kulkarni breaks down the three core regulatory pillars required to bypass PBM middlemen without triggering federal anti-kickback statutes. We discuss the "one-year commitment" rule, the "seeding" trap, and why your current marketing strategy might be an unintentional red flag for regulators. If you are in Life Sciences commercialization, the "wait and see" approach is now your biggest liability. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 In this episode of KLF Deep Dive, Darshan Kulkarni uncovers the catastrophic risks clinical trial sites face when they fail to vet their staff against federal exclusion lists. We move beyond simple compliance to discuss the "off-the-books" penalties that can end a career or a company. If you’re in the life sciences, this is the legal shield you can't afford to ignore. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Undeclared allergens remain the #1 cause of food recalls in the U.S., yet many brands still treat labeling as a "marketing" task rather than a "legal" one. In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the regulatory horror stories of major brands—from Nugo to Frito-Lay—and explains why the FDA doesn't care if your co-manufacturer messed up. If your name is on the bag, you own the risk.

Learn how to transition from "marketing font arguments" to FSMA-compliant allergen controls that survive federal scrutiny.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focusing solely on HIPAA leaves a massive, unregulated gap in your compliance strategy. We break down the "layered system" of risk—from aggressive state privacy laws and medical privacy statutes to the DOJ’s massive 2025 Bulk Data Rule. Whether you’re running patient engagement campaigns or leveraging marketing automation, you’ll learn why the tools you use to scale might be the very tools that trigger a regulatory audit. Don't leave your firm's reputation to a "narrow slice" of engagement. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 The "handshake" era of cosmetic compliance is officially over. Under new authorities in Sections 605, 610, and 704, the FDA has moved from simple observation to an aggressive "access and copy" mandate. In this episode, Darshan Kulkarni breaks down the "SAHCOD" threat and explains why your internal communications, medical assessments, and even cross-contamination logs are now fair game for federal investigators. If you handle raw materials or shared manufacturing equipment, your entire catalog could be at risk of a forensic audit. Learn where the FDA's power ends—and where your defense begins. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 In clinical research, if it isn't documented, it never happened. Many site owners mistake a competent team for a compliant one—a mistake that leads to disastrous FDA inspections and lost sponsor contracts. In this KLF Deep Dive, Darshan Kulkarni reveals the specific training SOPs, log templates, and contract clauses required to protect your site. Learn how to bridge the gap between "doing the work" and "proving the work" so you can demonstrate a culture of readiness that sponsors trust. 

Support the show

www.kulkarnilawfirm.com